This is not an approval of a new combination drug, just the approval of these two drugs in combination with carfilzomib. This allows Amgen to promote this combination to clinicians, rather than relying on off-label use.
Carfilzomib’s patent will still run out in 2025 when anyone can create and sell their own generic version of the drug. If Amgen are going to be able to compete against the generics they are going to need something new and very special. I wonder where they might find something like this?
- Forums
- ASX - By Stock
- RAC
- Ann: Expanded Heart Protection Discovery for Zantrene
Ann: Expanded Heart Protection Discovery for Zantrene, page-142
-
- There are more pages in this discussion • 245 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.79 |
Change
-0.075(4.02%) |
Mkt cap ! $304.8M |
Open | High | Low | Value | Volume |
$1.86 | $1.86 | $1.76 | $348.2K | 192.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5612 | $1.77 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.79 | 3567 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5612 | 1.770 |
2 | 3718 | 1.760 |
1 | 1709 | 1.755 |
1 | 6191 | 1.750 |
1 | 332 | 1.740 |
Price($) | Vol. | No. |
---|---|---|
1.790 | 3567 | 1 |
1.830 | 1000 | 1 |
1.840 | 4543 | 2 |
1.890 | 7332 | 2 |
1.905 | 2032 | 1 |
Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
Last
$1.78 |
  |
Change
-0.075 ( 5.38 %) |
|||
Open | High | Low | Volume | ||
$1.81 | $1.86 | $1.76 | 27553 | ||
Last updated 15.55pm 14/06/2024 ? |
Featured News
RAC (ASX) Chart |